Slingshot members are tracking this event:

FDA has placed Bluebird bio's (BLUE) studies of elivaldogene autotemcel (eli-cel, Lenti-D) for cerebral adrenoleukodystrophy (CALD) on clinical hold following safety report

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks

Slingshot Insights Explained
Catalyst Date
Occurred on:
Aug 09, 2021
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Elivaldogene Autotemcel, Cerebral Adrenoleukodystrophy